D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for simufilam in mild-to-moderate Alzheimer’s disease ...

Boral Capital LLC, effective November 08, 2024. D. Boral Capital continues to offer its full suite of market leading investment bank/broker dealer capabilities through its holding Company ...

TACLOBAN CITY — A parasitic disease endemic to Eastern Visayas continues to affect residents of the region. In a report released on Oct. 24, the Department of Health in Eastern Visayas (DOH-8 ...